Most Read Articles
02 Jul 2018
The use of beta-blockers in patients with heart failure with preserved ejection fraction (HFpEF), especially in those without histories of myocardial infarction, appears to increase the risk of adverse cardiovascular events, according to a recent study.
07 Jul 2018
Younger women with ST-segment elevation myocardial infarction (STEMI) appear to have poorer 30-day survival compared with younger men, a study has shown. However, this association weakens after age 60 years and is no longer observed in oldest women.
27 Jun 2018
A higher frailty index score and frailty status is associated with 1-year mortality risk in patients who underwent transcatheter aortic valve replacement (TAVR), according to a recent study.
6 days ago
Use of thiazolidinediones does not lead to a significant reduction in incidence of atrial fibrillation (AF) among patients with diabetes and coronary disease, a recent study has found.

Crystal-proven gout linked to cardiovascular disease

05 Jul 2018

A robust association exists between crystal-proven gout and increased prevalence of cardiovascular disease (CVD), a recent study has found. Additionally, characteristic gout severity factors correlate with CVD in patients with gout.

Data were obtained from a total of 700 gout patients and 276 controls. CVD was present in 47 percent (95 percent CI, 44–51 percent) of gout patients and 24 percent (19–29 percent) of controls. After adjusting for confounders, the strong correlation persisted between gout and an increased prevalence of CVD (odds ratio, 3.39; 2.37–4.84).

The following factors were independently associated with prevalent CVD (p<0.05) in patients with gout: disease duration ≥2 years, oligo- or polyarthritis, serum urate acid >0.55 mmol/l at presentation, and joint damage.

In this study that sought to assess the prevalence of CVD in patients with crystal-proven gout vs arthritis controls, the authors consecutively included patients with arthritis referred for diagnosis in the Gout Arnhem-Liemers cohort. Joint analysis was conducted in all referred patients, and controls were negative for crystals.

The authors also collected patients’ characteristics and different manifestations of CVD as well as gout severity factors (eg, disease duration, attack frequency, tophi, affected joints, high serum urate acid level and joint damage). They then compared gout patients with controls for the prevalence of CVD. Finally, an analysis was performed on the association between characteristic gout severity factors and presence of CVD.

A 2017 study suggested that gout patients with CVD were more likely to have additional comorbidities, more gout-related symptoms and a delay in treatment initiation, which may be associated with greater severity of disease. [J Manag Care Spec Pharm 2017;23:677-683]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
02 Jul 2018
The use of beta-blockers in patients with heart failure with preserved ejection fraction (HFpEF), especially in those without histories of myocardial infarction, appears to increase the risk of adverse cardiovascular events, according to a recent study.
07 Jul 2018
Younger women with ST-segment elevation myocardial infarction (STEMI) appear to have poorer 30-day survival compared with younger men, a study has shown. However, this association weakens after age 60 years and is no longer observed in oldest women.
27 Jun 2018
A higher frailty index score and frailty status is associated with 1-year mortality risk in patients who underwent transcatheter aortic valve replacement (TAVR), according to a recent study.
6 days ago
Use of thiazolidinediones does not lead to a significant reduction in incidence of atrial fibrillation (AF) among patients with diabetes and coronary disease, a recent study has found.